spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  acetylcholine 

 HSMN NewsFeed - 23 May 2022
MindMed Appoints Schond L. Greenway as Chief Financial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Apr 2022
MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2021
Oyster Point Pharma Announces FDA Approval of TYRVAYA(TM) (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 30 Sep 2020
Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2020
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Apr 2020
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 24 Jul 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 24 Jan 2018
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Jan 2017
Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 6 Jan 2017
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Nov 2016
Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 17 Feb 2016
Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 24 Dec 2014
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Jul 2014
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1
Biopharmaceuticals Dermatology Distribution
 HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Dec 2012
Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2012
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR(R) and Donepezil for Alzheimer’s Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Apr 2012
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2011
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
Biopharmaceuticals
 HSMN NewsFeed - 29 Jul 2010
Shionogi Inc. Announces FDA Approval of CUVPOSA for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jun 2010
QR Pharma Completes $2.4 Million Seed Financing with Round-Closing Investments from BioAdvance and Angels to Advance Clinical Development of two Alzheimer's Disease Compounds
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 19 Apr 2010
BioMarin Launches Firdapse in the European Union
Biopharmaceuticals
 HSMN NewsFeed - 16 Dec 2009
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 30 Nov 2009
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Oct 2009
Ipsen Announces the Launch of Dysport(R) (abobotulinumtoxinA) in the United States for the Treatment of Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 9 Sep 2009
EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Apr 2009
FDA Approves Dysport(TM) for Therapeutic and Aesthetic Uses
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Mar 2009
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Feb 2009
The Health Authorities of 15 European Countries Give a Collective Green Light to Azzalure For the Treatment of Glabellar Lines, Paving the Way for National Marketing Authorizations
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 13 Oct 2008
New Data Shows Abbott's Bioabsorbable Drug Eluting Stent is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Feb 2008
Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2008
Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jan 2008
Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport(R) in Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2008
Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States
Biopharmaceuticals
 HSMN NewsFeed - 27 Dec 2007
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 6 Dec 2007
Ipsen Grants Galderma Exclusive Rights to Promote and Distribute Dysport(R) in Aesthetic Medicine and Dermatological Indications in Brazil, Argentina and Paraguay
Biopharmaceuticals Distribution Dermatology
 HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 19 Oct 2007
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 26 Sep 2007
EnVivo Pharmaceuticals Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Announces Co-Promotion Agreement for Balsalazide
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Jun 2007
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Jun 2007
CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President of Strategic and Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2007
Neuro-Hitech, Inc., Obtains Exclusive License to Combination Drugs for the Treatment of Alzheimer's Disease and Other Serious Neurological Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 15 May 2007
Solstice Neurosciences, Inc. Announces Commercialization Agreement
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2007
CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Mar 2007
GTC Biotherapeutics Grants Expanded License to PharmAthene for Further Development of Protexia(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Mar 2007
Xytis Enrolls First Patient in Phase II Clinical Study With Anatibant (XY2405) for Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Mar 2007
Myriad Presents Additional Flurizan(TM) Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Feb 2007
Athenagen Announces Name Change to CoMentis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Jan 2007
Xytis Begins Phase II Clinical Study with Anatibant (XY2405) for Traumatic Brain Injury
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 5 Jan 2007
Xytis Pharmaceuticals Names Dr. Vincent F. Simmon President, Chief Executive Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2006
U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Jul 2006
Exelon(R) Patch, the first transdermal therapy for Alzheimer's disease, may provide a promising new approach to treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Jul 2006
Myriad's 24-Month Study of Flurizan Demonstrates Significant Benefit in Alzheimer's Disease Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Jun 2006
The U.S. Food and Drug Administration Approves Exelon(R) (rivastigmine tartrate) as the First Medication Indicated to Treat Parkinson's Disease Dementia
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 17 May 2006
FDA Advisory Committee Recommends Approval of Exelon(R) (rivastigmine tartrate) in the Treatment of Dementia Associated with Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 16 May 2006
Leuprolide Acetate Stabilizes Cognitive and Functional Decline in Women With Alzheimer's Disease, Study Shows
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 May 2006
Athenagen Announces the Appointment of John Donovan as Chief Financial Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 55

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 55 additional stories matching:
acetylcholine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.